EDS and Mast Cells

Ehlers-Danlos Syndrome (EDS) is a group of inherited connective tissue disorders affecting collagen structure and function. The most common type associated with MCAS and POTS is hypermobile EDS (hEDS).

Collagen Basics

Collagen is the most abundant protein in the human body — roughly 30% of total protein mass. It’s the structural scaffold of connective tissue: skin, tendons, ligaments, blood vessel walls, gut lining, organ capsules, bone matrix. It provides tensile strength (resistance to stretching).

Collagen molecules are triple helices — three polypeptide chains wound around each other, then cross-linked into fibrils, then bundled into fibers. The strength comes from the cross-links and the regular, tight packing of the triple helix.

In classical EDS types (cEDS, vEDS), specific collagen gene mutations are identified — COL5A1, COL5A2 (classical), COL3A1 (vascular). These produce collagen that is structurally defective in known, measurable ways.

In hypermobile EDS (hEDS), the genetic basis has not been identified. The clinical presentation — generalized joint hypermobility, chronic pain, tissue fragility, slow wound healing — strongly suggests a connective tissue defect, but the specific molecular target is unknown. This makes hEDS a clinical diagnosis based on criteria (currently the 2017 International Consortium criteria) rather than a genetic test.

Why Mast Cells Care About Connective Tissue

Mast Cells don’t just pass through connective tissue — they’re permanent residents. They mature, differentiate, and live embedded in the extracellular matrix. The matrix provides:

Mechanical signals: The stiffness, stretch, and deformation of the surrounding matrix affects mast cell behavior. Mast cells have mechanosensitive ion channels. When the tissue stretches or deforms, calcium influx can trigger or prime Degranulation.

Chemical signals: The extracellular matrix contains proteoglycans, glycosaminoglycans, and matricellular proteins that interact with mast cell surface receptors. These interactions regulate mast cell survival, maturation, mediator content, and activation threshold.

Positional context: In normal connective tissue, mast cells are spaced and oriented in ways that allow appropriate surveillance without cross-activation. In structurally abnormal tissue, this architecture may be disrupted.

Proposed Mechanisms Linking EDS to MCAS

Altered mechanotransduction: If collagen is more compliant (stretchier) than normal, tissues deform more during routine activity — walking, standing, breathing, gut peristalsis. This increased deformation may provide chronic low-grade mechanical activation of embedded mast cells.

Matrix-receptor signaling changes: Abnormal extracellular matrix composition may fail to provide inhibitory signals or may expose activating ligands that normal matrix would shield. The “neighborhood” the mast cell lives in changes its behavior.

Vascular fragility: EDS-associated blood vessel laxity may cause microvascular dysfunction, creating local hypoxia or reperfusion events that activate mast cells.

Increased tissue trauma: Hypermobile joints and fragile tissues experience more micro-injuries during normal activity. Tissue damage activates mast cells as part of wound healing — but if the tissue is being micro-injured constantly, the wound-healing response never fully turns off.

Evidence status

These mechanisms are proposed, not proven. The clinical co-occurrence of hEDS and MCAS is widely recognized by specialists who treat both conditions. The molecular explanation for why they co-occur is still being worked out. No study has definitively demonstrated that abnormal collagen directly causes mast cell overactivation in humans.

The Structural Consequences

EDS isn’t just about joint flexibility. Connective tissue is everywhere, so structural defects manifest broadly:

• Gut: Connective tissue in the gut wall → GI dysmotility, gastroparesis, visceral prolapse. Mast cells in a structurally abnormal gut wall compound the GI symptoms of MCAS.
• Blood vessels: Lax vessel walls → venous pooling → POTS. Also potentially Histamine-mediated vasodilation on an already compliant vascular bed = more severe hemodynamic instability.
• Skin: Velvety, fragile skin that bruises easily. Heparin release from activated mast cells further impairs clotting → worsened bruising.
• Nervous system: Nerves travel through connective tissue. Structural changes may contribute to nerve compression, traction injuries, or Small Fiber Neuropathy.

Diagnosis

hEDS is diagnosed clinically using the 2017 criteria, which include:

• Beighton score ≥5 (a standardized measure of joint hypermobility)
• Systemic features of connective tissue disorder
• Exclusion of other connective tissue diagnoses
• Positive family history or musculoskeletal complications

There is no genetic test for hEDS. Other EDS types can be confirmed genetically.